Loading patent…
AssigneeAlfa Wassermann S.p.A.
InventorsBruno Baggio, Giorgio Bazzato, Agostino Fracasso, Giovanni Gambaro, Egidio Marchi, Gianfranco Tamagnone
Estimating the term…
The use of some glycosaminoglycans like sulodexide, low molecular weight heparin and low molecular weight dermatan sulfate and of the medicines by parenteral use that contain them in the treatment of patients suffering from chronic renal insufficiency subjected to peritoneal dialysis is described. The effectiveness of this use has been shown both by pharmacological studies carried out in nephrectomized rats to whom a peritoneal damage has been caused and by clinical studies carried out in patients suffering from chronic renal insufficiency subjected to CAPD and treated by intraperitoneal route (i.p.) with 2 ml vials of VESSEL DUE F.RTM. containing 50 mg of sulodexide. A significant increase of the peritoneal transports of urea and of creatinine joined to a significant decrease of the protein-loss in the peritoneal effluent has been observed. Significant changes of the ultrafiltration capacity and of haemorrhagic-coagulative complications have not been observed during the study.
A method of reducing the structural and functional degeneration of the peritoneal membrane of patients suffering from chronic renal insufficiency which comprises the intraperitoneal administration of therapeutically effective amounts of glycosaminoglycans selected from the group consisting of sulodexide, low molecular weight heparin and low molecular weight dermatan sulfate during the treatment of peritoneal dialysis whereby an increase of excretion of urea and creatinine and a lowering of loss of proteins are achieved.
A method of reducing the structural and functional degeneration of the peritoneal membrane of a patient suffering from chronic renal insufficiency, said patient being subjected to peritoneal dealysis, which consists of administering intraperitoneally to said patient an effective amount of a glycosaminoglycan selected from the group consisting of sulodexide, low molecular weight dermatan sulfate whereby an increase of excretion of urea and creatinine and a lowering of loss of proteins are achieved.
Dependencies are inferred from the claim text.